Glucophage (Metformin Hydrochloride)

Glucophage is indicated for the management of type 2 diabetes mellitus in adults.

• Improves glycemic control as part of a comprehensive diabetes treatment plan.
• Can be used alone (monotherapy) or in combination with other oral antidiabetic agents.
• May be prescribed when diet, exercise, and weight management alone are insufficient.
• Often chosen for patients with overweight or obesity due to its weight-neutral or modest weight‑loss effect.
• May be used in patients with mild to moderate renal impairment, following dose adjustment guidelines.

The safety profile of Glucophage includes both common, generally mild reactions and less frequent, potentially serious events.

Common

• Nausea or upset stomach
• Diarrhea
• Metallic taste in the mouth
• Abdominal discomfort or cramping
• Decreased appetite

Serious

• Lactic acidosis (rare but potentially fatal)
• Severe hypoglycemia when used with insulin or sulfonylureas
• Persistent vomiting leading to dehydration
• Hepatic dysfunction (elevated liver enzymes)

When prescribing Glucophage, healthcare providers consider several precautionary measures to minimize risks and ensure appropriate use.

• Assess renal function before initiation and periodically during therapy.
• Evaluate liver enzymes, especially in patients with a history of hepatic disease.
• Use caution in patients with a history of alcohol abuse or heart failure.
• Adjust dose in elderly patients due to altered pharmacokinetics.
• Counsel patients on the importance of consistent dietary patterns to reduce gastrointestinal upset.
• Discontinue the drug before any radiologic procedure that uses iodinated contrast agents.

Glucophage may interact with other medicines, affecting its effectiveness or increasing the risk of adverse events. Understanding which agents to avoid and which require careful monitoring helps maintain optimal glycemic control.

Avoid

• Iodinated contrast media used for imaging studies (risk of acute renal failure).
• Cimetidine (may increase metformin plasma concentrations).
• Trimethoprim-sulfamethoxazole (may increase metformin levels).
• Certain antivirals such as dolutegravir (potential pharmacokinetic interaction).

Use with caution

• Insulin or sulfonylureas (enhanced risk of hypoglycemia).
• Diuretics (potential for dehydration and lactic acidosis).
• ACE inhibitors or ARBs (monitor renal function).
• Beta‑blockers (may mask hypoglycemia symptoms).
• Alcohol consumption (increases risk of lactic acidosis).